De øvrige fire undersøgelser omfattede 1 894 patienter, der var i dialyse og i forvejen havde fået lægemidler til stimulation af dannelsen af røde blodlegemer.
The other four studies (in 1,894 patients) were carried out in patients on dialysis who had already been receiving medicines to stimulate red blood cell production.